Table 1 Life expectancy gains from cancer prevention strategies for BRCA1/2 positive women
From: Risk-reducing strategies for women carrying brca1/2 mutations with a focus on prophylactic surgery
Author and year | Mutation type | Type of prophylactic intervention vs. surveillance | Life expectancy gain (year) |
|---|---|---|---|
Sonnenberg et al 1993 | BRCA 1/2 | Tamoxifen for 5 years | 1.6 to 2.2 |
Schrag et al 1997 | BRCA1/2 | Bilateral Mastectomy Bilateral oophorectomy | 2.9 to 5.3 0.3 to 1.7 |
Grann et al 1998 | BRCA1/2 | Bilateral oophorectomy Bilateral mastectomy Bilateral mastectomy and oophorectomy | 0.4 to 2.6 2.8 to 3.4 3.3 to 6.0 |
Grann et al 2000 | BRCA1/2 | Bilateral oophorectomy Bilateral mastectomy Bilateral oophorectomy and mastectomy Chemoprevention with tamoxifen Chemoprevention with raloxifene | 0.9 ( 95% CI: 0.4-1.2) 3.4 (95% CI: 2.7-3.7) 4.3 (95% CI: 3.6-4.6 ) 1.6 (95% CI: 1.0-2.1) 2.2 (95% CI: 1.3-2.8 ) |
Schrag et al 2000 | BRCA1/2 | Tamoxifen for 5 years Bilateral oophorectomy Contra-lateral mastectomy | 0.4 to 1.3 0.2 to 1.8 0.6 to 2.1 |
van Roosmalen et al 2002 | BRCA1/2 | Bilateral mastectomy and oophorectomy Breast screening and bilateral oophorectomy Bilateral mastectomy with ovarian screening | High risk: 11.7. Medium risk 6.6 High risk: 9.5. Medium risk 5.3 High risk: 4.9. Medium risk 4.4 |
Armstrong et al 2004 | BRCA1/2 | Bilateral oophorectomy Bilateral mastectomy and prophylactic oophorectomy | 3.34 to 4.65 5.49 to 7.63 |